Business Standard

Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23

Torrent Pharmaceuticals
Premium

Torrent Pharma’s US revenues were up by 24 percent during the quarter to Rs 291 crore, while in constant currency terms it was up 13 percent.

Sohini Das Mumbai
Ahmedabad-based Torrent Pharmaceuticals posted a 14 per cent rise in net profit for the third quarter of the 2022-23 fiscal to Rs 249 crore on the back of good growth in the India and Brazil markets.

Torrent Pharma’s revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23.

India, Torrent’s key market, grew by 17 per cent to Rs 1,259 crore including revenues from the integration of its recently acquired outfit Curatio Healthcare (a dermatology firm). “Field force has been further expanded and

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 25 2023 | 10:45 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com